Company intelligence / Profile preview

BIOLIFE4D

Chicago, Illinois, United Statesbiolife4d.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

BIOLIFE4D has developed a process to use a patient's own cells to bioprint functional human heart tissue and ultimately whole hearts. The company’s current focus includes building mini-hearts for cardiotoxicity testing and progressing toward full organ replacement. No clinical trial results have been reported as the company remains in the development/preclinical phase

Therapeutic areas: Cardiovascular
Modalities: 3D bioprinting of organs (using patient-derived cells)tissue engineeringregenerative medicine
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on BIOLIFE4D.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOLIFE4D.

Explore the full profile